--- title: "Regeneron Fianlimab Trial Fails: What 1,455 REGN Holders Now See" type: news slug: regeneron-fianlimab-phase3-melanoma-fail canonical_url: https://13finsight.com/news/regeneron-fianlimab-phase3-melanoma-fail published_at: 2026-05-18T12:42:30.118Z updated_at: 2026-05-18T12:42:33.532Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 770 locale: en source: 13F Insight --- # Regeneron Fianlimab Trial Fails: What 1,455 REGN Holders Now See > Regeneron's fianlimab+Libtayo combo missed its primary PFS endpoint vs Keytruda at p=0.0627. The data angle is in who has to defend the position — and who already trimmed. Regeneron Pharmaceuticals said on May 16 that its Phase 3 trial of fianlimab — its in-house LAG-3 inhibitor — combined with the company's PD-1 drug Libtayo failed to beat Merck's Keytruda on the primary progression-free survival endpoint in first-line unresectable or metastatic melanoma. Median PFS came in at 11.5 months on the high-dose combination versus 6.4 months on Keytruda, but the p-value of 0.0627 sits just outside the pre-specified statistical bar. The shares opened sharply lower on May 18, the first full trading day after the readout.The news-wire version of this story is straightforward: a defining catalyst missed, an analyst note titled shaking heads, and a queue of sell-side downgrades. The ownership read on REGN's institutional base is more interesting, because the 1,455 13F holders we track were already positioned for a binary outcome — and the shape of that positioning tells you who was forced to defend the trade through the print versus who pre-trimmed.The active book is unusually concentrated for a $80B-plus biotechStrip out passive index mandates and what's left at the top of REGN's institutional roster is a relatively short list of high-conviction active managers. Of the top 20 reported holders, 18 are flagged as active in our classification — but the dollar weight inside that group is anchored by a handful of names that have to make a real fundamental decision this week, not an index-rebalancing one.The single largest position we surface that isn't an index trust is Dodge & Cox at roughly $3.4B in reported REGN value. Dodge & Cox runs a deep-value, long-hold mandate; a Phase 3 miss on a candidate that was central to the next leg of the franchise is precisely the kind of event that triggers their internal investment-committee re-underwrite rather than a same-week exit. Their next quarterly 13F will tell you whether they treated the miss as a thesis break or a price-improvement opportunity.Behind Dodge & Cox sits JPMorgan Chase at $3.2B across its asset-management complex — a mix of active and quant sleeves that will not all move in the same direction. State Street's $3.6B is a different animal: that figure is dominated by SPDR ETFs and other index-tracked products and should not be read as conviction. Same caveat applies to the $6.9B held by BlackRock and the $5.1B held by Vanguard Capital Management — those are largely index-mandate positions, and they will only move when REGN's S&P 500 or sector ETF weights move.What our data does not yet showNo active Schedule 13D or 13G filing has been triggered on REGN in the dedup window — there is no activist crossing the 5% line, and no recent insider Form 4 transactions in our index either. That matters for two reasons.First, in the typical pharma post-failure pattern, the next 30 days are when bargain-hunting healthcare-focused funds occasionally cross the 5% Schedule 13G threshold quietly. Watch the aggregate signal feed for any Edgar pings on REGN in the back half of May — that is the leading indicator of an active fund treating the miss as a buy-the-fundamental-floor event.Second, the absence of recent insider buys is a real data point, not a missing one. C-suite buying immediately into a failed late-stage readout is one of the strongest contrarian signals in biotech; the fact that no Regeneron insider has stepped up yet is consistent with internal teams still working through the failure analysis. If a buy lands in the next two weeks, it will be visible inside hours.The franchise math, not the headline mathThe fianlimab program is not over. Regeneron's own May 16 release flagged that the higher-dose Phase 3 head-to-head against Bristol Myers Squibb's Opdualag is continuing, with overall-survival benefit and primary response-rate endpoints still ahead. That is the realistic path back. The investment question is whether the next 18 months of Eylea HD ramp and Dupixent label expansion are enough to absorb the consensus haircut to fianlimab's peak-sales contribution.Sell-side will rebuild their models this week. The 13F window that closes June 30 — and prints in mid-August — is the one to mark on the calendar. Dodge & Cox's Q2 disclosure will be the single most-watched line on REGN's holder file. A flat or modestly added position from them is the green light a number of fast-money funds are quietly waiting on.SEC sourceRegeneron's own press release on the GlobeNewswire wire is the primary document — May 16, 2026 Regeneron fianlimab Phase 3 update. A formal 8-K disclosure of the trial outcome typically follows within four business days; REGN's EDGAR 8-K feed is where it will land.Track Regeneron's full institutional ownership and recent activity as the post-failure 13F window plays out. ## FAQ ### What happened with Regeneron's fianlimab melanoma trial? Regeneron's Phase 3 trial of fianlimab combined with Libtayo missed its primary progression-free survival endpoint versus Merck's Keytruda in first-line metastatic melanoma. Median PFS was numerically longer at 11.5 months on the high-dose combo versus 6.4 months on Keytruda, but the result missed statistical significance at p=0.0627. ### Why did REGN stock drop on May 18, 2026? REGN shares opened sharply lower on May 18 as the market re-priced fianlimab's peak-sales contribution after the Phase 3 melanoma readout. Analysts described the miss as a defining-catalyst failure and began cutting price targets, even though a separate head-to-head Phase 3 versus Bristol Myers Squibb's Opdualag is still ongoing. ### Who are the largest active institutional holders of Regeneron? Among the top 20 institutional holders of REGN, 18 are classified as active managers. The largest non-index active position is Dodge & Cox at roughly $3.4 billion in reported 13F value, followed by JPMorgan Chase asset-management subsidiaries at $3.2 billion. BlackRock, Vanguard and State Street appear larger by dollars but those positions are dominated by index-mandate ETFs. ### Is fianlimab development over for Regeneron? No. Regeneron's May 16 update confirmed that a separate Phase 3 trial comparing the high-dose fianlimab combination to Bristol Myers Squibb's Opdualag continues, with overall-survival benefit and response-rate endpoints still ahead. Management is positioning that trial as the path back for the LAG-3 inhibitor program. --- Source: 13F Insight — https://13finsight.com/news/regeneron-fianlimab-phase3-melanoma-fail Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-18T12:42:33.532Z